Skip to main content

Changchun BCHT Biotechnology Co.

Changchun BCHT Biotechnology Co., established in 2004 and located in Changchun, is a biopharmaceutical enterprise engaging in research, development, production and marketing of vaccines, biologics and peptide drugs.

BCHT has well-established innovative platform by the most talented researchers and with the state-of-the-art facility. The management team consists of the members with strong international background and extensive experience in China in biopharmaceutical industry. BCHT owns among the most advanced R&D laboratories and pilot plants for vaccines and peptide drugs in China. Currently, there are two vaccines, varicella and rabies, in the market and many products, such as HIV vaccine and LAIV vaccine, in its developing pipeline at the different stages. The manufacturing plant, production process and quality assessment and control are fully with the compliance of GMP requirements and some products aim at receiving WHO prequalification in the near future.

BCHT has established a wide cooperation with international partners for technology promotion and product marketing. For example, LAIV is the project collaborated with WHO. The company’s products have received the certificate or are in the process of registration for the permit of market access in many countries. BCHT is to strategically explore the international market and business opportunity with the partners.